Drug profile · INN
bevacizumab-maly
ALYMSYS
bevacizumab-maly (ALYMSYS) is a vascular endothelial growth factor a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — bevacizumab-maly
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
bevacizumab-maly (ALYMSYS) is a vascular endothelial growth factor a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor A inhibitor
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bevacizumab-maly?
bevacizumab-maly (ALYMSYS) is a vascular endothelial growth factor a inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for bevacizumab-maly?
ALYMSYS is a marketed brand name for bevacizumab-maly. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bevacizumab-maly?
bevacizumab-maly has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.